Drugs / 18F-FTC-146
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02753101 | Feb 2016 → Feb 2017 | complex regional pain syndrome, sciatica | Stanford University | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06599151 | Oct 2024 → Oct 2030 expected | neuralgia, neuropathy, painful | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04314856 | Jan 2021 → Jun 2022 | fragile X syndrome | Guido A. Davidzon, MD, SM | Withdrawn | No outcome recorded |
| Phase 1 | NCT03649555 | Feb 2019 → Mar 2020 | — | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT03556137 | Jul 2018 → Dec 2024 | neurological pain disorder, neuropathy, painful, radiculopathy, spinal cord disorder | Stanford University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04365660 | Jan → May 2021 | osteosarcoma | Davidzon, Guido, M.D. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18-F -FTC 146 | “For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final...” NCT04365660 ↗ |
| Modality | Diagnostic / imaging agent | “PET radiopharmaceutical \[18F\]FTC-146” NCT02753101 ↗ |
| Route | Intravenous | “10 mCi± 1 mCi of \[18F\]FTC-146 intravenously” NCT02753101 ↗ |